Characteristics | Tocilizumab | Etanercept | Adalimumab | p |
---|---|---|---|---|
No. patients (female/male, n) | 22 (19/3) | 21 (18/3) | 21 (18/3) | 0.79 |
Age, yrs, mean (SD) | 62 (16) | 61 (15) | 63 (17) | 0.77 |
Disease duration, mo, mean (SD) | 10 (6) | 11 (5) | 9 (5) | 0.79 |
RF-positive, % | 89.2 | 88.6 | 85.8 | 0.61 |
ACPA-positive, % | 71.2 | 68.2 | 69.2 | 0.79 |
ESR, mm/h, mean (SD) | 38 (9) | 39 (8) | 37 (8) | 0.69 |
CRP, mg/l, mean (SD) | 27.8 (11.2) | 26.7 (10.8) | 26.1 (10.5) | 0.68 |
HAQ, mean (SD) | 1.38 (0.32) | 1.35 (0.31) | 1.37 (0.34) | 0.78 |
DAS28, mean (SD) | 5.22 (1.6) | 5.17 (1.5) | 5.34 (1.4) | 0.57 |
Current smokers, % | 22 | 16 | 19 | 0.25 |
BMI, kg/m2, mean (SD) | 18.2 (5.3) | 20.1 (4.9) | 19.5 (5.1) | 0.76 |
Systolic BP, mmHg, mean (SD) | 127.9 (21) | 125.5 (18) | 128.3 (20) | 0.59 |
Diastolic BP, mmHg, mean (SD) | 68.8 (13.3) | 65.5 (14.3) | 70.9 (14.4) | 0.59 |
Heart rate bpm, mean (SD) | 68.2 (18) | 72.2 (19) | 72.2 (18) | 0.81 |
ABI, mean (SD) | 1.12 (0.21) | 1.21 (0.22) | 1.15 (0.16) | 0.62 |
T/H ratio | 4.51 | 4.52 | 4.32 | 0.68 |
Total cholesterol, mg/dl | 221 (31.2) | 217 (26.2) | 216 (25.4) | 0.78 |
HDL cholesterol, mg/dl | 49 (5.2) | 48 (4.9) | 50 (5.1) | 0.89 |
CAVI, mean (SD) | 10.72 (1.22) | 10.69 (1.33) | 10.66 (1.43) | 0.89 |
Alx@75 (%), mean (SD) | 38.1 (5.4) | 37.7 (6.2) | 37.9 (4.3) | 0.82 |
CIMT, mm, mean (SD) | 1.1 (0.1) | 1.1 (0.1) | 1.1 (0.2) | 0.97 |
CAP, (number with each combined grade 0/1/2/3/4) | 9/10/2/1/0 | 7/7/5/1/1 | 10/8/2/1/0 | 0.57 |
RF: rheumatoid factor; ACPA: anticitrullinated protein antibodies; ESR: erythrocyte sedimentation rate; CRP: C-reactive protein; HAQ: Health Assessment Questionnaire; DAS: Disease Activity Score; BMI: body mass index; BP: blood pressure; ABI: ankle-brachial index; TC: total cholesterol; HDL: high-density lipoprotein cholesterol; T/H: ratio of fasting serum to TC to HDL; CAVI: cardio-ankle vascular index; AIx: augmentation index; CIMT: carotid intima-media thickness; CAP: carotid artery plaque.